Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug.
The Warburg effect refers to the phenomenon whereby cancer cells avidly take up glucose and produce lactic acid under aerobic conditions. Although the molecular mechanisms underlying tumor reliance on glycolysis remains not completely clear, its inhibition opens feasible therapeutic windows for cancer treatment. Indeed, several small molecules have emerged by combinatorial studies exhibiting promising anticancer activity both in vitro and in vivo, as a single agent or in combination with other therapeutic modalities. Therefore, besides reviewing the alterations of glycolysis that occur with malignant transformation, this manuscript aims at recapitulating the most effective pharmacological therapeutics of its targeting. In particular, we describe the principal mechanisms of action and the main targets of 3-bromopyruvate, an alkylating agent with impressive antitumor effects in several models of animal tumors. Moreover, we discuss the chemo-potentiating strategies that would make unparalleled the putative therapeutic efficacy of its use in clinical settings.
Department of Biology, University of Rome Tor Vergata, Via della Ricerca Scientifica, 00133 Rome, Italy.
Simone
S
Cardaci
Enrico
E
Desideri
Maria Rosa
MR
Ciriolo
D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology*; D006019:Glycolysis / Q000187:drug effects*; D006801:Humans; D053858:Metabolic Networks and Pathways / Q000502:physiology*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D011773:Pyruvates / Q000378:metabolism / Q000494:pharmacology*
D018906:Antineoplastic Agents, Alkylating; D011773:Pyruvates; C017092:bromopyruvate